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Escalating the dose of chemotherapy could increase response rate
and, possibly, survival in some tumour types (Gurney et al, 1993),
usually with a higher degree of haematological toxicity. The recent
spread of dose-intensive treatments has stimulated the research of
possible means to reduce degree and/or duration of haematological
toxicities. Some of these methods, such as administration of
haemopoietic growth factors, granulocyte colony-stimulating
factor (G-CSF), or granulocyte–macrophage CSF (GM-CSF), or
transfusion of autologous blood stem cells, have already entered
common daily practice (Canellos, 1994). Other methods are still
investigational, such as new growth factors (stem cell factor or
FLT-3 ligand), concomitant administration of potentially myelo-
protective agents (amifostine and seraspenide) (Capizzi et al,
1993; Genevay et al, 1996), bone marrow inhibitors (MIP-1a) or
transfection of stem cells with multidrug resistant (MDR) genes
(Jelinke et al, 1996).
A myeloprotective and immuno-enhancing effect of the pineal
neuro-hormone melatonin in in-vitro and in-vivo models has been
recently described (Maestroni et al, 1994b). In physiological
conditions, melatonin is secreted by the pineal gland with a circa-
dian rhythm and it has recently received renewed interest because
of some demonstrated (induction of sleep), or claimed, properties
(anti-aging or anti-tumour activity) (Arendt, 1996; Brzezinski,
1997). In medical oncology, melatonin has been given either in
combination with interleukin-2 (IL-2) or interferon to patients
with melanoma and renal cell cancer, and alone or in association
with chemotherapy in patients with lung cancer or brain metastasis
(Lissoni et al, 1989; Lissoni et al, 1992; Aldeghi et al, 1994; Neri
et al, 1994).
In tumour-bearing mice treated with cyclophosphamide, etopo-
side or carboplatin, the association of melatonin with chemotherapy
was shown to abrogate leucopenia and thrombocytopenia without
affecting anti-tumour activity (Maestroni et al, 1994b). The myelo-
protective effect was more pronounced when melatonin was given
concomitantly rather than after chemotherapy. In vitro experiments
on haemopoietic stem cells suggested that this effect was obtained
through inhibition of apoptosis, mediated by a mechanism involving
T-helper cells and GM-CSF (Maestroni et al, 1994a). This effect
seems to be dependent on opioid cytokines released by T-helper
cells after stimulation with melatonin, and is similar to the effect of
both IL-4 and dynorphin (Maestroni et al, 1996).
The present study was performed to verify if the myeloprotec-
tive effect of melatonin observed in mice could be reproduced in
humans receiving chemotherapy. Previously untreated patients
with inoperable lung cancer were scheduled to receive two cycles
of carboplatin and etoposide, at dosages known to induce response
but at the price of a severe myelosuppression. Patients were
randomly assigned to receive either melatonin or placebo at the
first cycle, with cross over to the other treatment at the second
cycle.
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Summary A significant myeloprotective effect of melatonin in mice treated with etoposide, cyclophosphamide or carboplatin has been
reported. The present study was designed to evaluate if the same effect could be observed in patients receiving chemotherapy. Twenty
previously untreated patients with inoperable lung cancer received two cycles of carboplatin (given at area under the curve 5 by the Calvert
formula) on day 1 and etoposide (150 mg m–2 i.v.) on days 1–3 every 4 weeks. Melatonin 40 mg or placebo (double-blind) was given orally in
the evening for 21 consecutive days, starting 2 days before chemotherapy. Patients were randomized to receive melatonin either with the first
or the second cycle. Complete blood cell count with differential was done three times per week for 3 weeks. The median age of the cohort was
60 years (range 42–69), 16 patients had non-small cell and four patients small-cell lung cancer, 12 stage III and eight stage IV disease. In a
multivariate analysis including age, sex, diagnosis, stage, performance status, doses of carboplatin and etoposide, and concomitant
treatment with melatonin or placebo, the haematological parameters – depth and duration of toxicity for haemoglobin, platelets and
neutrophils (ANC) – were not significantly different between cycles with/without melatonin. The mean ANC nadir and the mean number of
days with ANC < 0.5 ´ 109 l–1 were 0.5 ´ 109 l–1 and 2.5 days, respectively, with/without melatonin. We concluded that, in patients with lung
cancer, melatonin given orally at a dose of 40 mg per day for 21 days in the evening, does not protect against the myelotoxic effect of
carboplatin and etoposide.
Keywords: myelotoxicity; chemotherapy; hormones; melatonin
1058
British Journal of Cancer (1999) 80(7), 1058–1061
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0463
Received 28 July 1998
Revised 27 November 1998
Accepted 4 December 1998
Correspondence to: M Ghielmini
Presented in part at the annual meeting of the American Society of Clinical
Oncology 1997.Myeloprotective effect of melatonin 1059
British Journal of Cancer (1999) 80(7), 1058–1061 © 1999 Cancer Research Campaign 
MATERIALS AND METHODS
Eligibility criteria included age of 18–70 years, histological or
cytological diagnosis of non-small-cell (NSCLC) or small-cell
(SCLC) lung cancer not amenable to surgery or radiotherapy, no
previous chemotherapy or radiotherapy, normal blood counts and
normal serum creatinine. In case of undifferentiated small-cell
histology, or in case of bone metastases, evidence of uninvolved
bone marrow by trephine biopsy was required. Concomitant treat-
ment with radiotherapy, steroids, haemopoietic growth factors or
investigational agents was not allowed. Patients were asked for
written informed consent and the trial was approved by the local
ethical authorities.
Chemotherapy consisted of two cycles of carboplatin (5 areas
under the curve (AUC) by the Calvert formula) (Crinò et al, 1995)
on day 1 and etoposide (150 mg m–2 intravenously (i.v.)) on days
1–3 given in the morning every 4 weeks. The doses administered
in the first cycle had to be repeated in the second cycle without any
dose adjustment, provided the creatinine clearance was in the
normal range. Patients showing non-haematological toxicity
³ grade 3 according to NCI–CTC criteria or haematological toxi-
city leading to hospitalization (haemorrhage or neutropenic fever)
at the first cycle, went off study.
Melatonin was provided by Helsinn Chemicals (Biasca,
Switzerland) as gelatin capsules containing 40 mg of the active
substance in a corn oil suspension. Placebo capsules had the same
aspect and content except for melatonin. To assure stability,
capsules were kept in a –20°C freezer; patients were instructed to
keep them in the refrigerator. During the treatment, melatonin or
placebo had to be taken orally in the evening (20:00 h), starting
2 days before chemotherapy for a total of 21 consecutive days.
Treatment was coded, and capsules were kept and distributed by
the research nurse who was in charge of the registration and
randomization; neither the nurse, the patient nor the investigator
were aware of the nature of the content. Patients were randomly
assigned to receive melatonin or placebo at the first cycle, with
cross over to the other treatment at the second cycle, to avoid that
results could be influenced by a cumulation of myelotoxicity.
Patients were on study up to 4 weeks after the second cycle.
During the study, patients had weekly clinical controls, with
complete blood cell count with differential three times a week until
complete haematological recovery (white blood count > 4 ´ 109 l–1
and platelets > 100 ´ 109 l–1). Chemistry, including creatinine, liver
function tests (LFT), glucose and PT were measured weekly. Formal
disease assessment was planned after the two cycles, or before if
clinically indicated. After the first two cycles, patients could be
treated according to the physician’s preference. For those wishing it,
unblinded melatonin was available from the 3rd cycle on.
Statistical analysis was performed by analysis of covariance
(ANCOVA) for repeated (paired) observations after confirming
the appropriateness of the assumption of normal distribution. The
regression models were calculated with age (as continuous vari-
able), sex, diagnosis (NSCLC vs SCLC), stage (III vs IV), perfor-
mance status (0 vs I), dose of carboplatin and etoposide (mg m–2 as
continuous variable) melatonin or placebo and order of melatonin
administration (at 1st or 2nd cycle) as independent variables. A
random effect for patients was also included in the model.
Statistical analysis was performed with the package ‘Stata’ (Stata
Corp., Texas, 1997).
The study has been performed without formal sample-size
computations. With the available sample-size of 20, a paired t-test
would have an 80% (or 90%) power to detect a change in a given
haematological parameter of the order of 65% (or 75%) of the
standard deviation of the observations (Machin and Campbell,
1987). Given the analytical approach used here, even smaller
effect sizes might have been detected.
RESULTS
Twenty-eight patients entered the study and eight (three with
SCCL and five with NSCCL) were not evaluable for the effect of
melatonin because of discontinuation of treatment after the first
cycle (disease progression: five patients; excessive toxicity: three
patients, all haematological).
The characteristics of the 20 patients with evaluable first and
second cycles are summarized in Table 1. Eight patients had
distant metastases, without bone marrow involvement in all of
them. Table 2 reports the doses of carboplatin and etoposide
administered at the first and second cycle with/without melatonin.
The doses were equivalent in all groups; in particular, the dose of
carboplatin was superimposable if it was calculated according to
surface area or to Calvert formula. The apparent raise at the second
cycle in the dose of carboplatin if calculated according to AUC
was due to a reduction of the mean value of the creatinine
clearance from 108 ml min–1 to 97 ml min–1. In the multivariate
analysis, the effect of carboplatin dose remained the same if calcu-
lated per mg m–2 or according to AUC. The median dose of mela-
tonin per day was of 0.6 mg kg–1 per day (range 0.4–0.8).
Overall, chemotherapy was well-tolerated, despite the signifi-
cant dosages of etoposide administered, and no patient needed
erythrocyte or platelet transfusions. Two patients (one at the first
cycle, given with melatonin and the other at the second cycle,
without concomitant melatonin) had to be hospitalized because of
febrile neutropenia.
The observed means and standard deviations of the haemato-
logical parameters of interest for both melatonin and placebo are
Table 1 Characteristics of evaluable patients (n = 20)
Median age (years) 60
Range 42–69
Male/Female 15/5
Small-cell/non-small-cell 4/16
Stage
III 12
IV 8
Performance status
01 3
17
Table 2 Mean (± s.d.) doses of carboplatin and etoposide
Etoposide Carboplatin Carboplatin
(mg m–2) (mg m–2) (AUC)
1st cycle 430 ± 36 373 ± 74 4.8 ± 0.5
2nd cycle 430 ± 36 333 ± 78 5.2 ± 1.4
Without melatonin 430 ± 36 354 ± 75 5.3 ± 1.4
With melatonin 420 ± 44 348 ± 65 4.9 ± 0.11060 M Ghielmini et al
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reported in Table 3. The mean ANC nadir was 0.5 ´ 109 l–1 and the
mean number of days with ANC < 0.5 ´ 109 l–1 was 2.5, both
without and with melatonin; mean platelets nadir was 121 ´ 109 l–1
without and 134 ´ 109 l–1 with melatonin, and the number of days
with platelets under 100 ´ 109 l–1 was respectively 1.5 and 1.0. The
ANCOVA models demonstrate the lack of significance of the small
variations observed with the adjunction of melatonin (Table 3). The
haematological toxicity of the second cycle was, as expected,
slightly higher, but the difference was not statistically significant.
In the regression analysis, the only variables significantly influ-
encing haematological toxicity were age, which was associated
with a prolongation of ANC nadir (P = 0.03), and worse perfor-
mance status, associated with a deeper ANC nadir (P = 0.007).
No changes of PT, glucose or LFT were seen, while a 10%
reduction in creatinine clearance was noted from the first to the
second cycle, but not between cycles with or without melatonin.
Ten of the 28 patients entered in the trial (36%) achieved partial or
complete response.
DISCUSSION
The purpose of this randomized, double-blind trial was to evaluate
the myeloprotective effect of melatonin in patients receiving
chemotherapy. The rationale of the trial was represented by the
previous experimental work of some of the authors demonstrating
a myeloprotective effect of melatonin in tumour-bearing mice and
in haematopoietic clonogenic cells in vitro (Maestroni et al, 1994a,
1994b). To mimic the experimental situation we administered
melatonin before, during and after chemotherapy, until the
expected day of recovery from neutropenia, for a total of 21 days.
The dose of melatonin selected (40 mg per day) is much higher
than the one shown to have physiological activity on sleep
troubles, and is associated with biological effects in the immune
system (Brzezinski, 1997), but it is nearer to the one tested in
animals to evaluate myeloprotection (1 mg kg–1) and equal to the
one used in previous trials in cancer patients (Lissoni et al, 1994).
In the present study, chemotherapy with carboplatin and etopo-
side was generally well-tolerated, with few subjective side-effects,
and haematological toxicity in the range of what is usually
observed. The overall response rate (36%) was as expected for
this type and stage of disease (Ihde, 1992; Crinò et al, 1995),
suggesting that melatonin did not affect anti-tumour activity.
Even though neutropenia and thrombocytopenia showed a high
interpatient variability, the concomitant administration of mela-
tonin did not significantly affect the pattern of myelotoxicity: the
mean (± s.d.) of ANC nadir and the mean number of days with an
ANC < 0.5 ´ 109 l–1 were 0.5 ± 0.4 ´ 109 l–1 and 0.5 ± 0.3 ´ 109 l–1
and 2.5 ± 2.8 days in cycles with/without melatonin respectively.
Even though we used a dose lower than the one tested in animals
(0.6 mg kg–1 orally vs 1 mg kg–1 s.c. in the mouse) we believe
that the dose used should have been active. The ingestion of 40-mg
capsules is, in fact, known to result in plasma concentrations much
above the physiological ones for more than 8 h (Waldhauser et al,
1984; Aldhous et al, 1985), and which have been associated with
some biological activities, such as activation of some lymphocyte
subsets in cancer patients (Lissoni et al, 1994).
We chose to give melatonin in the evening, in order to maintain
its physiological circadian rhythm, but this timing could have
affected its myeloprotective effect; in fact, the administration of
melatonin concomitantly to chemotherapy might have a higher
myeloprotective effect through its antioxidant action. We can
therefore not exclude that the same trial, if performed with mela-
tonin given in the morning, or shortly before chemotherapy, could
have given different results.
In conclusion, our work demonstrates the lack of a protective
effect of melatonin, given orally at a dose of 40 mg per day for 21
days in the evening, on the haematological toxicity induced by
carboplatin and etoposide in patients with lung cancer.
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